BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target
BTIG analyst Marie Thibault reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.
Share
Why It Matters
An expert who studies Edwards Lifesciences still thinks the company is worth buying and should reach $110 per share. This shows the analyst believes the company will keep doing well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.